SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF
FOREIGN ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
the month of January 2007
Commission
File Number 000-51122
pSivida
Limited
(Translation
of registrant’s name into English)
Level
12
BGC Centre
28
The
Esplanade
Perth
WA
6000
(Address
of principal executive offices)
(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F).
Form
20-F x Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No x
If
"Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ___.
The
document attached as Exhibit 99.1 to this Report on Form 6-K is hereby
incorporated by reference herein and into the following registration statements:
(i) the Registrant's Registration Statement on Form F-3, Registration No.
333-132776; (ii) the Registrant's Registration Statement on Form F-3,
Registration No. 333-132777; and (iii) the Registrant's Registration Statement
on Form F-3, Registration No. 333-135428.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
Date:
January 24, 2007
|
pSivida
Limited
|
||
| |
|
|
| By: | /s/ Michael J. Soja | |
|
Michael J. Soja |
||
| Vice President of Finance and Chief Financial Officer | ||
EXHIBIT
INDEX
|
EXHIBIT
99.1:
|
Press
Release: pSivida appoints Boston based Managing
Director
|
|
ASX/Media
RELEASE
|
24
January 2007
|
pSivida
appoints Boston based Managing Director
Dr.
Roger Brimblecombe retires as Non-executive Chairman and is replaced by Dr.
David J. Mazzo
Boston,
MA. and Perth, Australia - Global bio-nanotech company pSivida Limited (ASX:PSD,
NASDAQ:PSDV, Xetra:PSI) is pleased to announce that Dr Paul Ashton has been
appointed Managing Director of pSivida Limited effective immediately and will
be
located at the pSivida head office in Boston, MA. Dr. Ashton’s appointment is
part of the program of consolidation of management and increased focus of
operations instituted by the Board of Directors.
Concurrently,
Dr. Roger Brimblecombe, the Chairman of the Board of Directors, will retire
from
service to pSivida. Dr. Brimblecombe had agreed to postpone his retirement
from
the Board last year to accept the roles of Acting Executive Chairman and Acting
Chief Executive Officer on a temporary basis. With the aforementioned
appointment of Dr. Ashton as Managing Director and the election of Dr. David
J.
Mazzo as a successor Chairman of the Board, Dr. Brimblecombe’s planned departure
may now be effected.
Dr.
Ashton’s appointment follows the announcement in late December 2006 that the
Company had entered into an exclusive three months negotiation with a large
global pharmaceutical company to license pSivida’s drug delivery technologies in
a significant market opportunity. Dr. Ashton was most recently the Company’s
Executive Director of Strategy and formerly President, Chief Executive Officer
and a Director of Control Delivery Systems, the Boston based drug delivery
company pSivida acquired in January 2006. He received a B.Sc in chemistry from
Durham University, England, and a Ph.D. in pharmaceutical science from the
University of Wales.
Dr.
Mazzo
will assume his new role as Non-executive Chairman of the Company effective
immediately. He is currently President and CEO of Chugai Pharma USA, a
subsidiary of Chugai Pharmaceutical Company Limited (Japan), a part of the
Roche
group of companies. Dr. Mazzo is recognized for his strong scientific and
regulatory expertise and broad technical and managerial experience gained from
working in a variety of multi-cultural and multi-lingual environments in the
USA, Europe and Asia. He has served as a member of the Nasal Drug Products
subcommittee of the FDA Advisory Committee for Pharmaceutical Science and
presently serves as an advisor to or a Director of a number of academic and
publicly traded organisations.
These
appointments, together with the recent re-appointment of Dr. Roger Aston as
a
Non-executive Director to the pSivida Board, are expected to facilitate the
various funding and licensing initiatives that are being pursued by the Company.
This new leadership team, coupled with the significant steps taken recently
to
further minimize expenses while focusing on those activities to advance key
clinical programmes, are expected to contribute to progress toward building
renewed shareholder value in the near term.
-ENDS-
Released
by:
|
pSivida
Limited
Brian
Leedman
Director
of Investor Relations
pSivida
Limited
Tel:
+ 61 412 281 780
brianl@psivida.com
|
US
Public Relations
Beverly
Jedynak
President
Martin
E. Janis & Company, Inc
Tel:
+1 (312) 943 1100 ext. 12
bjedynak@janispr.com
|
European
Public Relations
Accent
Marketing Limited
Eva
Reuter
Tel:
+49 (254) 393 0740
e.reuter@e-reuter-ir.com
|
NOTES
TO EDITORS:
pSivida
is a global bio-nanotech company committed to the biomedical sector and the
development of drug delivery products. Retisert™ is FDA approved for the
treatment of uveitis. Vitrasert® is FDA approved for the treatment of
AIDS-related CMV Retinitis. Bausch & Lomb own the trademarks Vitrasert® and
Retisert™. pSivida has licensed the technologies underlying both of these
products to Bausch & Lomb. The technology underlying Medidur™ for diabetic
macular edema is licensed to Alimera Sciences and is in Phase III clinical
trials.
pSivida
owns the rights to develop and commercialize a modified form of silicon
(porosified or nano-structured silicon) known as BioSilicon™, which has
applications in drug delivery, wound healing, orthopedics, and tissue
engineering. pSivida’s subsidiary, AION Diagnostics Limited is developing
diagnostic products and the subsidiary pSiNutria is developing food technology
products both using BioSilicon™.
pSivida’s
intellectual property portfolio consists of 76 patent families, 95 granted
patents, including patents accepted for issuance, and over 300 patent
applications.
pSivida
conducts its operations from offices and facilities near Boston in the United
States, Malvern in the United Kingdom, Perth in Australia and Singapore.
pSivida
is listed on NASDAQ (PSDV),
the
Australian Stock Exchange (PSD)
and on
the Frankfurt Stock Exchange on the XETRA system (German Symbol:
PSI. Securities Code (WKN) 358705).
pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
Lynch Nanotechnology Index.
This
document contains forward-looking statements that involve risks and
uncertainties including with respect to the potential licensing of pSivida’s
drug delivery technologies to a large global pharmaceutical company; potential
market sizes and potential products, applications and regulatory approvals.
Although we believe that the expectations reflected in such forward-looking
statements are reasonable at this time, we can give no assurance that such
expectations will prove to be correct. Given these uncertainties, readers are
cautioned not to place undue reliance on such forward-looking statements. Actual
results could differ materially from those anticipated in these forward-looking
statements due to many important factors including: failure of the company
to
successfully negotiate and close a license of pSivida’s drug delivery
technologies to a large global pharmaceutical company; failure of any license
negotiated with a large global pharma to be in a significant market opportunity
. Other reasons are contained in cautionary statements in the Annual Report
on
Form 20-F filed with the U.S. Securities and Exchange Commission, including,
without limitation, under Item 3.D, "Risk Factors" therein. We do not undertake
to update any oral or written forward-looking statements that may be made by
or
on behalf of pSivida.